Free Trial
NASDAQ:ORGO

Organogenesis (ORGO) Stock Price, News & Analysis

Organogenesis logo
$5.10 +0.26 (+5.27%)
As of 03:44 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Organogenesis Stock (NASDAQ:ORGO)

Key Stats

Today's Range
$4.90
$5.15
50-Day Range
$3.23
$5.03
52-Week Range
$2.45
$6.71
Volume
341,013 shs
Average Volume
1.41 million shs
Market Capitalization
$646.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Moderate Buy

Company Overview

Organogenesis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

ORGO MarketRank™: 

Organogenesis scored higher than 86% of companies evaluated by MarketBeat, and ranked 169th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Organogenesis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Organogenesis has only been the subject of 2 research reports in the past 90 days.

  • Read more about Organogenesis' stock forecast and price target.
  • Earnings Growth

    Earnings for Organogenesis are expected to grow in the coming year, from ($0.07) to ($0.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Organogenesis is -36.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Organogenesis is -36.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Organogenesis has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Organogenesis' valuation and earnings.
  • Percentage of Shares Shorted

    15.25% of the float of Organogenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Organogenesis has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Organogenesis has recently increased by 0.51%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Organogenesis does not currently pay a dividend.

  • Dividend Growth

    Organogenesis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.25% of the float of Organogenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Organogenesis has a short interest ratio ("days to cover") of 8.6.
  • Change versus previous month

    Short interest in Organogenesis has recently increased by 0.51%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Organogenesis has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Organogenesis this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Organogenesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $725,732.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    33.00% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Organogenesis' insider trading history.
Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORGO Stock News Headlines

Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …tc pixel
Organogenesis Amends Credit Agreement Amid Revenue Decline
ORGO Sales Drop 23%
See More Headlines

ORGO Stock Analysis - Frequently Asked Questions

Organogenesis' stock was trading at $3.20 at the start of the year. Since then, ORGO shares have increased by 60.8% and is now trading at $5.1450.

Organogenesis (NASDAQ:ORGO) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.08. The business earned $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis had a negative net margin of 1.92% and a negative trailing twelve-month return on equity of 0.37%.
Read the conference call transcript
.

Top institutional investors of Organogenesis include Soleus Capital Management L.P. (9.73%), First Light Asset Management LLC (5.34%), Assenagon Asset Management S.A. (2.25%) and Acadian Asset Management LLC (1.91%). Insiders that own company stock include Albert Erani, Gary S Gillheeney, Lori Freedman, Michael Joseph Driscoll and Michael W Katz.
View institutional ownership trends
.

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Organogenesis investors own include NVIDIA (NVDA), Financial Select Sector SPDR Fund (XLF), Enterprise Products Partners (EPD), Advanced Micro Devices (AMD), Energy Transfer (ET), Moderna (MRNA) and Vaxart (VXRT).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGO
CIK
1661181
Fax
N/A
Employees
950
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$6.00
Potential Upside/Downside
+46.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$860 thousand
Net Margins
-1.92%
Pretax Margin
-5.01%
Return on Equity
-0.37%
Return on Assets
-0.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.95
Quick Ratio
3.45

Sales & Book Value

Annual Sales
$482.04 million
Price / Sales
1.35
Cash Flow
$0.22 per share
Price / Cash Flow
23.10
Book Value
$1.84 per share
Price / Book
2.79

Miscellaneous

Outstanding Shares
126,860,000
Free Float
84,995,000
Market Cap
$651.43 million
Optionable
Optionable
Beta
1.76

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ORGO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners